Prurigo nodularis

Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023

Retrieved on: 
Tuesday, September 26, 2023
Prurigo nodularis, Therapy, Patient, Skin, WCI, Pharmaceutical industry

HAMPTON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab in patients with prurigo nodularis (PN) has been accepted as an oral presentation at the 12th World Congress on Itch (WCI), being held in Miami on Nov 5-7, 2023.

Key Points: 
  • HAMPTON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab in patients with prurigo nodularis (PN) has been accepted as an oral presentation at the 12th World Congress on Itch (WCI), being held in Miami on Nov 5-7, 2023.
  • The Phase 1b multi-center, randomized, double-blind, placebo-controlled trial is designed to study barzolvolimab in patients with prurigo nodularis (PN), a chronic skin disease characterized by the development of hard, intensely itchy (pruritic) nodules on the skin.

INTERNATIONALLY RENOWNED DERMATOLOGIST AND PHYSICIAN SCIENTIST SHAWN KWATRA, MD, NAMED NEW CHAIR OF DERMATOLOGY AT THE UM SCHOOL OF MEDICINE AND CHIEF OF SERVICE OF DERMATOLOGY AT UM MEDICAL CENTER

Retrieved on: 
Monday, September 18, 2023
The New England Journal of Medicine, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Medical Affairs Bureau, Society, University of Maryland, College Park, Atopic dermatitis, Skin condition, Science, Maryland School, JAMA Dermatology, Hospital, Journal, Faculty, Prurigo nodularis, University, Physician, Service, Research, Paul Khavari, Johns Hopkins School of Medicine, Human musculoskeletal system, Knowledge, NIH, Skin, Duke University, Arthritis, Immunotherapy, FPI, University of Maryland School of Medicine, Diving Medical Advisory Council, MPH, University of Maryland Medical Center, Vinay Mohan Kwatra, UMMC, Wake Forest School of Medicine, Nature Medicine, UMMS, Joseph, Assistant professor, Pharmaceutical industry, Management, Medical device, Nursing, MD, Dermatology

Dr. Kwatra, who will begin the new role in early 2024, will hold the Joseph W. Burnett Endowed Professor and Chair in Dermatology.

Key Points: 
  • Dr. Kwatra, who will begin the new role in early 2024, will hold the Joseph W. Burnett Endowed Professor and Chair in Dermatology.
  • Dr. Kwatra joins UMSOM from Johns Hopkins University School of Medicine, where he served as the Founding Director of the Johns Hopkins Itch Center.
  • "It is an honor to be the next Chair of Dermatology at such a prestigious medical school," said Kwatra.
  • He earned his undergraduate degree from Duke University and his medical degree from Wake Forest University School of Medicine.

ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights

Retrieved on: 
Monday, August 14, 2023
IPO, Axial spondyloarthritis, IV, Spermatogenesis, Nektar Therapeutics, Doctor of Philosophy, Pain, Graves' ophthalmopathy, Psoriatic arthritis, Dermatology, Teprotumumab, MD, Patient, Randomized controlled trial, Prurigo nodularis, DMC, Disease, Tissue, SLRN, Disability, Human, IL-17A, Data, Hearing, Uveitis, Rheumatology, Growth, FDA, Safety, D, Secukinumab, Neutropenia, Exercise, POC, Eosinophilic esophagitis, Allergy, B cell, AAD, Webcast, CFO, Enthesitis, LOS, Research, Hives, Therapy, Inflammation, Huber loss, CU, Data monitoring committee, TED, Pharmaceutical industry, Vaccine, Management, Rare-earth element, HS, Part, Hidradenitis suppurativa

LOS ANGELES, Aug. 14, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reported financial results for the second quarter ended June 30, 2023 and highlighted additional recent corporate updates and milestones.   

Key Points: 
  • LOS ANGELES, Aug. 14, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reported financial results for the second quarter ended June 30, 2023 and highlighted additional recent corporate updates and milestones.
  • Enrollment of the double-blind, placebo-controlled Part B of the Phase 2b/3 trial evaluating izokibep in HS completed ahead of schedule, accelerating anticipated top-line results into the third quarter 2023.
  • Net Loss: Net loss totaled $26.0 million for the second quarter of 2023, compared to $14.5 million for the second quarter of 2022.
  • ET to review its second quarter 2023 financial results.

Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, August 8, 2023
Well, Hypersensitivity, Rockefeller University, Survival, G&A, Omalizumab, Angioedema, KIT, ILT4, Patient, Prurigo nodularis, R, Quality of life, Allergy, Research, European Academy of Allergy and Clinical Immunology, Eosinophil, Prurigo, Neoplasm, PD-1, Kinetics, Skin, Safety, D, Index, Eosinophilic esophagitis, CSU, Contingency, B cell, Cell, Hives, PCE, MTD, Itch, Therapy, Myelocyte, Dysphagia, Clinical trial, Esophagus, EAACI, PN, Physician, UCT, SD, Rare-earth element, Pharmaceutical industry, Vaccine, Beauty salon, Cryptocurrency, Video game, Dermatology

HAMPTON, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Key Points: 
  • - Phase 2 CSU enrollment completed; topline data by YE 2023 -
    HAMPTON, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.
  • In July 2023, Celldex announced that enrollment to the CSU study had been completed.
  • CSU EAACI 2023 Data Summary:
    At EAACI 2023 , data were presented on the complete 24 week experience for all patients.
  • In May 2023, Celldex announced that the first patient had been dosed in the Phase 1 study of CDX-585.

Trevi Therapeutics to Report Q2 2023 Financial Results and Provide a Corporate Update on August 10, 2023

Retrieved on: 
Thursday, August 3, 2023
Chronic cough, Webcast, EDT, Prurigo nodularis, Therapy, IPF, Patient, Idiopathic pulmonary fibrosis, News, Conference call, Pharmaceutical industry, Conference

NEW HAVEN, Conn., Aug. 3, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis, today announced that senior management will host a conference call and live audio webcast on Thursday, August 10, 2023, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the second quarter ended June 30, 2023.

Key Points: 
  • ET, to provide a corporate update and review the Company's financial results for the second quarter ended June 30, 2023.
  • To participate in the live conference call by phone, please dial (888) 317 6003 (domestic) or (412) 317 6061 (international) and provide access code 6064699.
  • A live audio webcast will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com .
  • An archived replay of the webcast will also be available for 30 days on the Company's website following the event.

Galderma Achieves Record 2 B USD Net Sales for a Six-Month Period in H1 2023, as It Continues to Demonstrate Leading Execution and Innovation Capabilities in Dermatology

Retrieved on: 
Thursday, July 27, 2023
Cosmetics, Retail, Health, Medical Devices, Other Health, Clinical Trials, Pharmaceutical, Galderma, COVID-19, Sleep, Dermatology, Core, American Academy, Atopic dermatitis, Biostimulation, Patient, Growth, Prurigo nodularis, FDA, Nemolizumab, III, Skin, Neuromodulation, Pharmaceutical industry, Security (finance), Marketing, International, Prurigo

With its broad portfolio of leading brands and services, fueled by science-based innovation and focused commercial execution, Galderma is well positioned in a growing dermatology market.

Key Points: 
  • With its broad portfolio of leading brands and services, fueled by science-based innovation and focused commercial execution, Galderma is well positioned in a growing dermatology market.
  • Injectable Aesthetics delivered single-digit constant currency growth over the period, from a high comparative base in 2022.
  • While Galderma gained market share across its Injectable Aesthetic portfolio, Neuromodulators and Biostimulators stood out with double-digit constant currency growth for the period.
  • In the first half of 2023, Galderma continued to advance innovation, with significant launches and positive data presentations across its leading dermatology portfolio.

Galderma @ WCD 2023: Late-Breaking Phase III Results for Nemolizumab Monotherapy in Prurigo Nodularis Show a Significant Proportion of Itch-Free Patients by Week 4

Retrieved on: 
Tuesday, July 4, 2023
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Prurigo nodularis, Congress, WCD, III, Patient, Galderma, Pharmaceutical industry, Dermatology

Galderma presented the latest data from its pivotal phase III OLYMPIA 2 trial at the 25th World Congress of Dermatology (WCD) in Singapore.

Key Points: 
  • Galderma presented the latest data from its pivotal phase III OLYMPIA 2 trial at the 25th World Congress of Dermatology (WCD) in Singapore.
  • The study met all primary and secondary endpoints, demonstrating that nemolizumab monotherapy significantly improved itch, skin clearance and sleep disturbance.
  • The safety profile was consistent with the phase II results.3
    Galderma also presented the results of two Galderma-sponsored studies on the significant impact of prurigo nodularis and itch on sleep disturbance at WCD.
  • These data demonstrate once again the massive burden those with prurigo nodularis face, and the extent of nemolizumab’s potential to address it.”

Trevi Therapeutics to Participate in Upcoming June Conferences

Retrieved on: 
Tuesday, May 30, 2023
University of Southern California, Critical Care Medicine (journal), Trevi, Keck School of Medicine of USC, Chronic cough, MD, Patient, Division, Prurigo nodularis, IPF, Therapy, Conference, Idiopathic pulmonary fibrosis, Pharmaceutical industry, HAVEN, Medicine

NEW HAVEN, Conn., May 30, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis, today announced senior management will attend and participate in the following conferences in June. In addition, Toby Maher, MD, Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California, will be presenting data from Trevi's Phase 2 CANAL trial in IPF chronic cough at the American Cough Conference on June 9th.

Key Points: 
  • NEW HAVEN, Conn., May 30, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis, today announced senior management will attend and participate in the following conferences in June.
  • In addition, Toby Maher, MD, Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California, will be presenting data from Trevi's Phase 2 CANAL trial in IPF chronic cough at the American Cough Conference on June 9th.
  • Presenters: Jennifer Good, President and CEO of Trevi Therapeutics, Farrell Simon, Chief Commercial Officer of Trevi Therapeutics, and Peter Dicpinigaitis, MD, Professor of Medicine, Albert Einstein College of Medicine, Division of Critical Care Medicine, Montefiore Medical Center, Director, Montefiore Cough Center and Editor-in-Chief, LUNG
    Registration: Investors and analysts can register to attend the in-person event by using the following link: https://ventures.yale.edu/yale-innovation-summit
    Presenter: Toby Maher, MD, Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California

Trevi Therapeutics to Present at Upcoming Yale Innovation Summit 2023

Retrieved on: 
Tuesday, May 9, 2023
Montefiore Medical Center, Q&A, Critical Care Medicine (journal), Trevi, Yale school, Yale School of Management, EDT, Cough, Chronic cough, MD, Patient, Division, Management, Prurigo nodularis, Therapy, IPF, Idiopathic pulmonary fibrosis, Pharmaceutical industry, Medicine

NEW HAVEN, Conn., May 9, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis, today announced its participation at the upcoming Yale Innovation Summit taking place from May 31 – June 1 at the Yale School of Management. The Company will present on its differentiated central and peripheral mechanism in cough and the potential broad translatability across cough indications. 

Key Points: 
  • The Company will present on its differentiated central and peripheral mechanism in cough and the potential broad translatability across cough indications.
  • Trevi's executives will be joined by one of the thought leaders in cough, Peter Dicpinigaitis, MD.
  • Dr. Dicpinigaitis will discuss the various central and peripheral pathways in cough and why a centrally active mechanism is generating such interest.
  • Trevi will also share insights on the patient and commercial potential of Haduvio with additional details from its physician and payer market research across chronic cough indications.

Trevi Therapeutics to Report Q1 2023 Financial Results and Provide a Corporate Update on May 11, 2023

Retrieved on: 
Thursday, May 4, 2023
Chronic cough, Webcast, EDT, Prurigo nodularis, IPF, Therapy, Idiopathic pulmonary fibrosis, News, Conference call, Pharmaceutical industry, Conference

NEW HAVEN, Conn., May 4, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced that senior management will host a conference call and live audio webcast on Thursday, May 11, 2023, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the first quarter ended March 31, 2023.

Key Points: 
  • ET, to provide a corporate update and review the Company's financial results for the first quarter ended March 31, 2023.
  • To participate in the live conference call by phone, please dial (888) 317 6003 (domestic) or (412) 317 6061 (international) and provide access code 0161285.
  • A live audio webcast will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com .
  • An archived replay of the webcast will also be available for 30 days on the Company's website following the event.